Kurma Partners
Kurma Partners is a management company specializing in the financing of innovation in healthcare and biotechnology.
Business Model:
Revenue: $12.7M
Employees: 11-50
Rankings
Detailed Kurma Partners Information
Kurma Partners was acquired by
Eurazeo.
The acquisition happend on 2021-09-24.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 24, Rue Royale
City: Paris
State: île-de-france
Zip: 75008
Country: FR
Financial Info
Stage:
Raised Last:
$0
Raised Total:$175M
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovations in Europe, particularly through links with many institutes. research and prestigious hospitals.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2014 | Xeltis | Series B | 33.5M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 11/2018 | Stilla Technologies | Series A | 18.3M |
| 4/2017 | DAMAE Medical | Seed Round | 0 |
| 9/2018 | Asarina Pharma | Post-IPO Equity | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 9/2017 | DNA Script | Series A | 13.2M |
| 2/2020 | Stilla Technologies | Series B | 0 |
| 7/2014 | Step Pharma | Seed Round | 3.4M |
| 12/2021 | Sunrise | Seed Round | 0 |
| 1/2020 | Sensome | Series B | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 11/2017 | Step Pharma | Series A | 17M |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 11/2015 | BioSerenity | Seed Round | 3.2M |
| 11/2017 | Coave Therapeutics | Series B | 22M |
| 7/2022 | Ganymed Robotics | Series B | 0 |
| 11/2015 | Advanced Perfusion Diagnostics | Seed Round | 1.7M |
| 6/2022 | Ermium Therapeutics | Series A | 0 |
| 11/2020 | Corlieve Therapeutics | Seed Round | - |
| 9/2019 | Ermium Therapeutics | Series A | 7M |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 1/2021 | IO Biotech | Series B | 0 |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 7/2017 | Cardiologs | Seed Round | 6.4M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 12/2015 | Xeltis | Series B | 3.3M |
| 9/2019 | Tacalyx | Seed Round | 7.7M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2013 | STAT-Dx | Series B | 28.9M |
| 7/2017 | Sensome | Seed Round | 3.4M |
| 11/2021 | Stilla Technologies | Debt Financing | 0 |
| 9/2018 | Minoryx Therapeutics | Series B | 0 |
| 10/2017 | FeetMe | Seed Round | 2.3M |
| 9/2019 | FeetMe | Series A | 10.4M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 12/2021 | Emergence Therapeutics | Series A | 0 |
| 4/2016 | STAT-Dx | Series C | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 11/2016 | OxThera | Series D | 34.1M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 7/2011 | ABM Pharma | Venture Round | 7.8M |
| 1/2015 | Orphazyme | Series B | 0 |
| 12/2014 | BliNK Biomedical | Series A | 5M |
| 12/2021 | Corteria Pharmaceuticals | Seed Round | 0 |
| 11/2020 | Lucine | Seed Round | 6.5M |
| 7/2020 | DeepUll | Series A | 3.9M |
| 6/2021 | Omnidoc | Seed Round | 3.7M |
| 7/2013 | PathoQuest | Series B | 5M |
| 3/2011 | PathoQuest | Series A | 2.8M |
| 3/2021 | Mila | Seed Round | 4.8M |
| 3/2017 | Orphazyme | Venture Round | 0 |
| 4/2011 | Asarina Pharma | Venture Round | - |
| 6/2018 | Sensome | Seed Round | 5.4M |
| 9/2019 | PathoQuest | Venture Round | 0 |
| 11/2016 | Asarina Pharma | Venture Round | 7.7M |
| 7/2018 | Safe Orthopaedics | Post-IPO Equity | 8.1M |
| 6/2022 | Charles.co | Seed Round | 0 |
| 1/2011 | Meiogenix | Series A | 1.6M |
| 1/2020 | Cardiologs | Series A | 15M |
| 5/2021 | Arkhn | Series A | 4.9M |
| 11/2016 | Advanced Perfusion Diagnostics | Series A | 3M |
| 3/2022 | FeetMe | Convertible Note | - |
| 5/2018 | PathoQuest | Venture Round | 0 |
| 2/2022 | DAMAE Medical | Series A | 5.7M |
| 3/2021 | Step Pharma | Series B | 0 |
| 11/2016 | Dynacure | Seed Round | 3.6M |
| 3/2021 | ARGOBIO | Funding Round | 0 |
| 10/2015 | Minoryx Therapeutics | Series A | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 5/2013 | Safe Orthopaedics | Venture Round | 2.6M |
| 5/2022 | Germitec SAS | Venture Round | 0 |
| 7/2017 | Safe Orthopaedics | Post-IPO Equity | - |
| 5/2021 | SmartCatch | Venture Round | 3.9M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 7/2021 | Coave Therapeutics | Series B | 0 |
| 12/2010 | Safe Orthopaedics | Series A | 7.9M |
| 9/2019 | Pharvaris | Series B | 66M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 7/2015 | PathoQuest | Venture Round | 0 |
| 7/2018 | Dynacure | Series A | 55.2M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 11/2021 | PathoQuest | Series B | 17.4M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 2/2021 | Medlumics | Venture Round | 21.8M |
| 11/2021 | PathoQuest | Series B | 0 |
| 11/2017 | Xeltis | Series C | 53M |
| 9/2011 | AM Pharma | Series D | 39.9M |
| 9/2014 | AM Pharma | Series E | 15.8M |
| 10/2022 | DeepUll | Series B | 12.7M |
| 4/2014 | OxThera | Venture Round | 10.6M |
| 1/2022 | NaoX Technologies | Venture Round | 4.8M |
| 7/2022 | Ganymed Robotics | Series B | 0 |
| 6/2022 | Charles.co | Seed Round | 0 |
| 6/2022 | Ermium Therapeutics | Series A | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 5/2022 | Germitec SAS | Venture Round | 0 |
| 2/2022 | DAMAE Medical | Series A | 0 |
| 1/2022 | NaoX Technologies | Venture Round | 0 |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 12/2021 | Sunrise | Seed Round | 0 |
| 12/2021 | Corteria Pharmaceuticals | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
